Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

Not available.

[1]  A. Verma,et al.  Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. List,et al.  The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. , 2019, Blood.

[3]  B. Fridley,et al.  Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. , 2018, The Lancet. Haematology.

[4]  D. Lipsker,et al.  Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. , 2018, Blood.

[5]  C. Shao,et al.  The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. , 2018, Molecular cell.

[6]  Sheng Wei,et al.  Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes , 2017, Haematologica.

[7]  J. Cleveland,et al.  The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. , 2016, Blood.

[8]  V. Dixit,et al.  Inflammasomes: mechanism of assembly, regulation and signalling , 2016, Nature Reviews Immunology.

[9]  J. Tavernier,et al.  Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. , 2016, Cancer research.

[10]  A. Stamatoullas,et al.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion , 2016, Leukemia.

[11]  A. Stamatoullas,et al.  Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. , 2016, Blood.

[12]  Katherine A. Fitzgerald,et al.  Unified Polymerization Mechanism for the Assembly of ASC-Dependent Inflammasomes , 2014, Cell.

[13]  R. Goldbach-Mansky,et al.  IL-1 blockade in autoinflammatory syndromes. , 2014, Annual review of medicine.

[14]  M. Shong,et al.  Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes , 2012, Diabetes.

[15]  Helen J. Lachmann,et al.  In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes , 2009, The Journal of experimental medicine.